New Delhi: CURO Biosciences Private Limited, trading as early signhas raised Rs 16 crore in pre-Series A funding from investor Ashish Kacholia. The financing, facilitated by DerivativeSaint, a private equity and venture capital advisory firm, highlights the company’s focus on early cancer detection.
This development positions CURO Biosciences to contribute to the global diagnostics market, which is estimated to grow significantly, reaching $250 billion by 2030.
ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions in as little as 15 minutes using a simple, non-invasive saliva sample. This innovative solution addresses the limitations of current diagnostic methods, which are often painful, time-consuming and expensive. ErlySign’s test kit promises a painless, affordable and immediate alternative for early cancer detection, offering hope for timely intervention and improved survival rates.
Speaking on the progress, Shubhendra Singh Thakur, CEO and Founder, ErlySign, said, “Our initial studies revealed exceptional results, achieving 100 percent specificity and 98.04 percent sensitivity. The product, now in the final stages of clinical trials at multiple HCG sites, promises to be a game-changer. “Beyond early detection, it will serve as a critical screening tool to eliminate unnecessary biopsies and invasive procedures.”
Funding will be critical to completing clinical trials, securing CDSCO approvals, and making ErlySign oral cancer screening kit to the market. In addition, it will support research and development, team expansion and the filing of new patents.
Looking ahead, ErlySign plans to leverage CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15 to 20 minutes. This cutting-edge technology has the potential to revolutionize cancer diagnosis making early detection accurate and accessible.